Olema Pharmaceuticals (OLMA) Other Accumulated Expenses (2020 - 2026)

Olema Pharmaceuticals (OLMA) has reported Other Accumulated Expenses for 7 consecutive years, with $42.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Accumulated Expenses rose 104.79% year-over-year to $42.5 million; the TTM figure through Mar 2026 stood at $42.5 million (up 104.79% YoY), while the FY2025 annual figure was $41.4 million, up 14.67% from the prior year.
• Other Accumulated Expenses advanced to $42.5 million in Q1 2026 per OLMA's latest filing, from $41.4 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $42.5 million in Q1 2026 and bottomed at $53000.0 in Q3 2022.
• Historically, Other Accumulated Expenses has averaged $17.3 million across 5 years, with a median of $17.7 million in 2023.
• Annual changes were most pronounced in 2023 — Other Accumulated Expenses sank 98.68% — and 2025, when it jumped 41123.61%.
• Olema Pharmaceuticals' Other Accumulated Expenses stood at $15.2 million in 2022, then advanced by 18.3% to $17.9 million in 2023, then soared by 101.43% to $36.1 million in 2024, then rose by 14.67% to $41.4 million in 2025, then grew by 2.58% to $42.5 million in 2026.
• Business Quant data shows OLMA's Other Accumulated Expenses at $42.5 million in Q1 2026, $41.4 million in Q4 2025, and $29.7 million in Q3 2025.